Immudyne Will Present at World Immune Regulation Meeting in Davos, Switzerland, March 18-21
March 15 2012 - 12:04PM
Immudyne, Inc. (Pink Sheets:IMMD) a leading industry provider of
all-natural products for immune system support from yeast
beta-glucan, today announced the Company will present the outcome
of Its clinical phase I and pivotal cancer studies at the World
Immune Regulator Meeting (WIRM) at the Congress Center in Davos,
Switzerland on March 18, 2012.
The special focus of the World Immune Regulation Meeting VI is
on Innate and Adaptive Immune Response and Role of Tissues in
Immune Regulation.
Additional recent company milestones include:
- PFK LLP, New York, completed audited Financials for years 2009
and 2010 (clean opinion)
- PKF LLP, New York in process of completing audited Financials
for 2011
- new corporate website: www.immudyne.com
- re-purchased and retired 3 million options
- upgraded OTC markets (www.otcmarkets.com) status to Fully
Current
- retirement of 1,136,842 shares in Q3/Q4
Immudyne has approximately 24 million shares outstanding. About
Immudyne
Immudyne makes immune system support products:
- all natural derived from yeast (notable the purest)
- protected by numerous patents/proprietary trade secret know
how
- Clinical evidence
- For pharmaceutical, nutraceutical, and topical/aesthetic
dermatological
- best in class/stable and reliable
Immudyne shares trade under the ticker symbol IMMD and the
Company can be found on the web at www.immudyne.com (currently
being transformed). Cautionary language regarding Forward-Looking
Statements Safe Harbor Act Disclaimer: Forward-looking statements
in this release are made pursuant to the Safe Harbor Provisions of
the Private Securities Litigation Reform Act of 1995. Certain
statements in this press release may contain words such as
"anticipates,""believes," "could," "estimates," "expects,"
"intends," "may," "projects," "plans," "targets" and other similar
language and are considered forward-looking statements. These
statements are based on management's current expectations,
estimates, and forecasts. These forward-looking statements are
subject to important assumptions, risks and uncertainties, which
are difficult to predict and therefore the actual results may be
materially different from those discussed.
CONTACT: Immudyne, Inc.
Mark McLaughlin
+1-914-714-8901
MarkMcL@immudyne.com